Welcome to our dedicated page for Accuray Incorp SEC filings (Ticker: ARAY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Accuray Incorporated (NASDAQ: ARAY) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures, including annual reports, quarterly reports and current reports on Form 8-K. As a radiation oncology company that develops and manufactures systems such as the CyberKnife and Radixact platforms, Accuray uses its SEC filings to report on financial performance, capital structure, governance decisions and material corporate events that matter to ARAY shareholders and analysts.
In its periodic reports, such as the Form 10-K and Form 10-Q, Accuray presents audited and unaudited financial statements, segment information, discussions of product and service revenue, gross profit, operating expenses, net income or loss, cash and debt balances, and non-GAAP measures like adjusted EBITDA. These filings also contain risk factor disclosures and management’s discussion and analysis, which address topics such as macroeconomic conditions, supply chain dynamics, tariffs, international operations and joint venture arrangements.
Current reports on Form 8-K provide more immediate insight into specific developments. Recent 8-K filings describe amendments to a financing agreement with TCW Asset Management Company LLC, including changes to liquidity calculations, delayed draw term loan conditions and covenant timing, as well as the issuance of warrants to purchase shares of common stock with defined exercise prices, terms and anti-dilution provisions. Other 8-Ks cover restructuring actions under a strategic, operational and organizational transformation plan, including workforce reductions and estimated restructuring charges, and governance matters such as equity incentive plan approvals, director elections, executive transitions and consulting arrangements.
Proxy materials, including the definitive proxy statement on Form DEF 14A, outline proposals submitted to stockholders, such as director elections, approval of the 2026 Equity Incentive Plan, advisory votes on executive compensation and ratification of the independent registered public accounting firm. These documents also describe corporate governance practices, board structure and executive compensation programs.
On Stock Titan, these filings are supplemented by AI-powered summaries that highlight key points from lengthy documents, helping users quickly understand the significance of each filing. Real-time updates from the SEC’s EDGAR system ensure that new 10-K, 10-Q and 8-K reports, as well as proxy statements and other relevant forms, are available as they are filed. For those tracking insider-related information, Form 4 and other ownership filings can be reviewed alongside financial and governance disclosures to build a more complete picture of Accuray’s regulatory and corporate history.
Accuray Incorporated reported that Sandeep Chalke has notified the company of his intent to resign from his role as Senior Vice President and Chief Commercial Officer. His resignation will be effective on March 31, 2026. The company states that his decision is not due to any disagreement with Accuray, its Board of Directors, or any matter related to its operations, policies, or practices. This is a leadership change disclosure and does not include financial results or transaction details.
Accuray director Byron C. Scott reported equity award activity tied to his retirement from the Board of Directors on December 31, 2025. On that date, 9,433 restricted stock units were converted into an equal number of common shares at an exercise price of $0, with vesting accelerated due to his retirement. Also on December 31, 2025, 3,774 common shares were withheld at $0.8246 per share to cover a cash settlement election under the grant agreement, reducing the reported common stock position to 158,953 shares held directly. Following these transactions, he also held 47,170 restricted stock units directly, including an award that vests 100% on November 13, 2026.
Accuray Incorporated updated its financing and launched a major restructuring as part of a broader transformation plan. The company amended its loan agreement to allow certain restricted cash to count toward Liquidity, remove the leverage condition for drawing on its delayed draw term loan facility, reduce delayed draw commitments to $18.25 million, and postpone testing of total leverage and fixed charge coverage covenants until the fiscal quarter ending December 31, 2026. Accuray also agreed to higher prepayment premiums, additional premiums totaling $1.9 million, and a $5 million temporary reduction in revolving credit availability through that date.
To induce lenders to enter into these changes, Accuray issued unregistered warrants for specified numbers of common shares at exercise prices of $1.50, $1.25 and $0.01 per share, expiring on December 15, 2032, and provided for additional warrants if delayed draw loans are funded, all with price-protection anti-dilution features. Separately, the company began the first phase of a strategic and organizational transformation, eliminating about 15 percent of its global workforce. It expects approximately $5.4 million in headcount-related restructuring costs and $5.6 million from other initiatives, for total charges of about $11 million across fiscal 2026, and disclosed that this first phase is expected to improve annualized operating profitability by approximately $25 million.
Accuray Inc. (ARAY)11/21/2025, 56,603 restricted stock units (RSUs) were converted into shares of Accuray common stock at an exercise price of $0, coded as an "M" transaction (option or derivative conversion).
After this conversion, Whitters beneficially owns 667,656 shares of Accuray common stock in direct ownership. Each RSU represents a contingent right to receive one share of common stock, and this RSU grant was structured to vest 100% on 11/21/2025, triggering the share issuance reported here.
Accuray Inc. (ARAY) director reports equity transactions in a Form 4. On 11/21/2025, the director settled 56,603 restricted stock units (RSUs), receiving the same number of shares of Accuray common stock at an exercise price of $0. On the same date, 22,642 shares of common stock were disposed of at $1.05 per share, described as shares forfeited due to a cash settlement election made in the grant agreement. After these transactions, the director beneficially owned 153,294 shares of Accuray common stock, held directly.
Accuray Inc. director transaction: A director of Accuray Inc. (ARAY) reported the vesting and settlement of 56,603 restricted stock units (RSUs) into shares of common stock on 11/21/2025. The RSUs converted at an exercise price of $0, meaning the director did not pay cash to receive the shares. Each RSU represented the right to receive one share of Accuray common stock and this RSU grant vested 100% on that date. Following this transaction, the director beneficially owned 212,659 shares of Accuray common stock in direct ownership.
Accuray Inc. director reports RSU vesting and share acquisition
A director of Accuray Inc. (ARAY) reported the vesting and settlement of restricted stock units into common stock. On 11/21/2025, 45,620 restricted stock units converted into 45,620 shares of Accuray common stock at an exercise price of $0, reported with transaction code "M," which indicates a derivative-to-equity conversion. Following this transaction, the director beneficially owns 400,229 shares of Accuray common stock in direct form. The reported restricted stock units were a grant that was scheduled to vest 100% on 11/21/2025, with each unit representing the right to receive one share of common stock.
Accuray Inc. director reports RSU vesting and share acquisition
A director of Accuray Inc. (ARAY), Anne Bryce Le Grand, reported the vesting of restricted stock units and related share acquisition. On 11/21/2025, 56,603 restricted stock units were converted to the same number of shares of Accuray common stock at an exercise price of $0, reported under transaction code "M." Each RSU represented a contingent right to receive one share of common stock and this RSU award vested 100% on that date.
Following this transaction, the reporting person beneficially owns 259,499 shares of Accuray common stock in direct form and no longer holds any of the reported derivative RSUs. This filing is a routine disclosure of insider equity compensation activity and ownership under the securities rules.
Accuray Inc. (ARAY) director Beverly A. Huss reported equity transactions involving company stock. On 11/21/2025, a grant of 56,603 restricted stock units (RSUs) was settled into an equivalent number of common shares at an exercise price of $0 per share. On the same date, 22,642 shares were forfeited, as noted, due to a cash settlement election made by the director in the grant agreement at a reported price of $1.05 per share. Following these transactions, the director directly beneficially owned 221,323 shares of Accuray common stock.
Each RSU represents a contingent right to receive one share of Accuray common stock, and the referenced RSU grant was scheduled to vest 100% on 11/21/2025.
Accuray Inc. (ARAY) director reports RSU vesting and share acquisition. A company director filed a Form 4 disclosing the conversion of 56,603 restricted stock units (RSUs) into an equal number of shares of Accuray common stock on 11/21/2025 through a transaction coded “M” (option or derivative exercise). The RSUs had an exercise price of $0, meaning the director did not pay cash to receive the shares. After this transaction, the director beneficially owns 294,804 shares of Accuray common stock in direct ownership. Each RSU represented a contingent right to receive one share, and this RSU grant vested 100% on 11/21/2025.